• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种Toll样受体9(TLR9)激动剂通过不同机制增强肽和脂肽疫苗的抗肿瘤免疫力。

A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms.

作者信息

Song Ying-Chyi, Liu Shih-Jen

机构信息

1] National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan [2] Research Center for Chinese Medicine &Acupuncture, China Medical University, Taichung, Taiwan.

1] National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan [2] Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.

出版信息

Sci Rep. 2015 Jul 28;5:12578. doi: 10.1038/srep12578.

DOI:10.1038/srep12578
PMID:26215533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4517169/
Abstract

The toll-like receptor 9 (TLR9) agonists CpG oligodeoxynucleotides (CpG ODNs) have been recognized as promising adjuvants for vaccines against infectious diseases and cancer. However, the role of TLR9 signaling in the regulation of antigen uptake and presentation is not well understood. Therefore, to investigate the effects of TLR9 signaling, this study used synthetic peptides (IDG) and lipopeptides (lipoIDG), which are internalized by dendritic cells (DCs) via endocytosis-dependent and endocytosis-independent pathways, respectively. Our data demonstrated that the internalization of lipoIDG and IDG by bone marrow-derived dendritic cells (BMDCs) was not enhanced in the presence of CpG ODNs; however, CpG ODNs prolonged the co-localization of IDG with CpG ODNs in early endosomes. Surprisingly, CpG ODNs enhanced CD8(+) T cell responses, and the anti-tumor effects of IDG immunization were stronger than those of lipoIDG immunization. LipoIDG admixed with CpG ODNs induced low levels of CD8(+) T cells and partially inhibit tumor growth. Our findings suggest that CpG ODNs increase the retention of antigens in early endosomes, which is important for eliciting anti-tumor immunity. These results will facilitate the application of CpG adjuvants in the design of different vaccines.

摘要

Toll样受体9(TLR9)激动剂CpG寡脱氧核苷酸(CpG ODNs)已被公认为是用于预防传染病和癌症疫苗的有前景的佐剂。然而,TLR9信号在调节抗原摄取和呈递中的作用尚未得到充分了解。因此,为了研究TLR9信号的作用,本研究使用了合成肽(IDG)和脂肽(lipoIDG),它们分别通过内吞作用依赖性和内吞作用非依赖性途径被树突状细胞(DCs)内化。我们的数据表明,在存在CpG ODNs的情况下,骨髓来源的树突状细胞(BMDCs)对lipoIDG和IDG的内化并未增强;然而,CpG ODNs延长了IDG与早期内体中CpG ODNs的共定位。令人惊讶的是,CpG ODNs增强了CD8(+) T细胞反应,并且IDG免疫的抗肿瘤作用比lipoIDG免疫更强。与CpG ODNs混合的lipoIDG诱导低水平的CD8(+) T细胞并部分抑制肿瘤生长。我们的研究结果表明,CpG ODNs增加了抗原在早期内体中的保留,这对于引发抗肿瘤免疫很重要。这些结果将有助于CpG佐剂在不同疫苗设计中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/cb8caf6047e8/srep12578-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/32807792fc84/srep12578-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/623dd2857bc1/srep12578-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/25d6222281d4/srep12578-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/43bca69494d2/srep12578-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/cb8caf6047e8/srep12578-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/32807792fc84/srep12578-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/623dd2857bc1/srep12578-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/25d6222281d4/srep12578-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/43bca69494d2/srep12578-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/487b/4517169/cb8caf6047e8/srep12578-f5.jpg

相似文献

1
A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms.一种Toll样受体9(TLR9)激动剂通过不同机制增强肽和脂肽疫苗的抗肿瘤免疫力。
Sci Rep. 2015 Jul 28;5:12578. doi: 10.1038/srep12578.
2
Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.硫代磷酸酯修饰的TLR9配体可保护癌细胞免受TRAIL诱导的凋亡。
J Immunol. 2009 Oct 1;183(7):4371-7. doi: 10.4049/jimmunol.0901436. Epub 2009 Sep 4.
3
Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.合成的CpG寡脱氧核苷酸作为TLR9激动剂用于免疫调节的治疗应用。
BioDrugs. 2007;21(6):387-401. doi: 10.2165/00063030-200721060-00006.
4
CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs.CpG-B寡脱氧核苷酸能有效诱导低水平的IFN-αβ,并能像CpG-A和CpG-C寡脱氧核苷酸一样有效地在树突状细胞中诱导IFN-αβ依赖性的MHC-I交叉提呈。
J Leukoc Biol. 2007 Apr;81(4):1075-85. doi: 10.1189/jlb.1006606. Epub 2007 Jan 16.
5
Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.脂质体包裹的CpG寡脱氧核苷酸作为诱导1型固有免疫的有效佐剂
Cancer Res. 2004 Dec 1;64(23):8754-60. doi: 10.1158/0008-5472.CAN-04-1691.
6
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.CpG 寡脱氧核苷酸作为 TLR9 激动剂:在过敏和哮喘中的治疗应用。
BioDrugs. 2010 Aug 1;24(4):225-35. doi: 10.2165/11536140-000000000-00000.
7
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.CpG寡脱氧核苷酸TLR9激动剂的免疫治疗应用
Adv Drug Deliv Rev. 2009 Mar 28;61(3):195-204. doi: 10.1016/j.addr.2008.12.008. Epub 2009 Jan 13.
8
Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell.CDK2 的选择性上调对于 TLR9 信号刺激的人肺癌细胞增殖至关重要。
Immunol Lett. 2010 Jan 4;127(2):93-9. doi: 10.1016/j.imlet.2009.10.002. Epub 2009 Oct 23.
9
Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.寡脱氧核苷酸 CpG 基序中的修饰导致 Toll 样受体 7 和 9 的拮抗活性。
J Med Chem. 2009 Aug 27;52(16):5108-14. doi: 10.1021/jm900730r.
10
TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.TLR9激动剂作为预防性和治疗性疫苗的佐剂
Curr Opin Mol Ther. 2007 Feb;9(1):45-52.

引用本文的文献

1
Adjuvant activity of cordycepin, a natural derivative of adenosine from on an inactivated rabies vaccine in an animal model.虫草素(一种腺苷的天然衍生物)对动物模型中灭活狂犬病疫苗的佐剂活性。
Heliyon. 2024 Jan 12;10(2):e24612. doi: 10.1016/j.heliyon.2024.e24612. eCollection 2024 Jan 30.
2
TLR9 signalling activation via direct ligation and its functional consequences in CD4 + T cells.TLR9 信号通路的直接配体激活及其在 CD4+T 细胞中的功能后果。
Scand J Immunol. 2022 Nov;96(5). doi: 10.1111/sji.13214. Epub 2022 Aug 25.
3
Magic Peptide: Unique Properties of the LRR11 Peptide in the Activation of Leukotriene Synthesis in Human Neutrophils.

本文引用的文献

1
Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells.TLR2 介导的树突状细胞内抗原交叉呈递的分子机制。
J Immunol. 2014 May 1;192(9):4233-41. doi: 10.4049/jimmunol.1302850. Epub 2014 Mar 28.
2
Mannose receptor 1 mediates cellular uptake and endosomal delivery of CpG-motif containing oligodeoxynucleotides.甘露糖受体 1 介导含有 CpG 基序的寡脱氧核苷酸的细胞摄取和内体递送。
J Immunol. 2013 Dec 1;191(11):5615-24. doi: 10.4049/jimmunol.1301438. Epub 2013 Nov 1.
3
TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
魔法肽:LRR11 肽在人嗜中性粒细胞白细胞三烯合成中的激活作用的独特特性。
Int J Mol Sci. 2021 Mar 6;22(5):2671. doi: 10.3390/ijms22052671.
4
HO-Inactivated RE88 Strain as a New Cancer Vaccine Carrier: Evaluation in a Mouse Model of Cancer.HO-灭活 RE88 株作为新型癌症疫苗载体:在癌症小鼠模型中的评估。
Drug Des Devel Ther. 2021 Jan 15;15:209-222. doi: 10.2147/DDDT.S282660. eCollection 2021.
5
Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge.肽聚糖处理的肿瘤抗原脉冲树突状细胞赋予完全抵抗肿瘤再挑战的能力。
Clin Exp Immunol. 2020 Sep;201(3):279-288. doi: 10.1111/cei.13468. Epub 2020 Jun 26.
6
Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll-Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells.抗菌肽 Omiganan 增强人外周血单个核细胞内体 Toll 样受体配体的干扰素反应。
Clin Transl Sci. 2020 Sep;13(5):891-895. doi: 10.1111/cts.12789. Epub 2020 Apr 21.
7
Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells.脂质体TLR9激动剂与TLR2激动剂融合抗原联合使用可通过树突状细胞调节肿瘤微环境。
Cancers (Basel). 2020 Mar 28;12(4):810. doi: 10.3390/cancers12040810.
8
A Potential Herbal Adjuvant Combined With a Peptide-Based Vaccine Acts Against HPV-Related Tumors Through Enhancing Effector and Memory T-Cell Immune Responses.一种潜在的草药佐剂与基于肽的疫苗联合作用,通过增强效应器和记忆 T 细胞免疫应答来对抗 HPV 相关肿瘤。
Front Immunol. 2020 Feb 20;11:62. doi: 10.3389/fimmu.2020.00062. eCollection 2020.
9
Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells.寡脱氧核苷酸ODN 2006和M362通过TLR-9/-6协同作用发挥强大的佐剂效应,以增强针对乳腺癌细胞的乳腺珠蛋白-A肽特异性细胞毒性CD8+T淋巴细胞反应。
Cancers (Basel). 2019 May 14;11(5):672. doi: 10.3390/cancers11050672.
10
Turning the Tide Against Regulatory T Cells.扭转针对调节性T细胞的局势。
Front Oncol. 2019 Apr 16;9:279. doi: 10.3389/fonc.2019.00279. eCollection 2019.
TLR7 触发多聚尿嘧啶核苷酸可通过增强抗原保存和树突状细胞表面 MHC I 类抗原的持久性,促进 CD8α+传统树突状细胞的交叉呈递。
J Immunol. 2013 Feb 1;190(3):948-60. doi: 10.4049/jimmunol.1102725. Epub 2013 Jan 2.
4
DEC-205 is a cell surface receptor for CpG oligonucleotides.DEC-205 是 CpG 寡核苷酸的细胞表面受体。
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16270-5. doi: 10.1073/pnas.1208796109. Epub 2012 Sep 17.
5
Development of antigen cross-presentation capacity in dendritic cells.树突状细胞中抗原交叉呈递能力的发展。
Trends Immunol. 2012 Aug;33(8):381-8. doi: 10.1016/j.it.2012.04.009. Epub 2012 Jun 5.
6
IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.IFN-α 通过调节抗原存活、内吞途径和加工来增强人树突状细胞的交叉呈递。
Blood. 2012 Feb 9;119(6):1407-17. doi: 10.1182/blood-2011-06-363564. Epub 2011 Dec 19.
7
Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo.树突状细胞呈递脂肽诱导体内抗肿瘤反应的一种非内吞依赖途径。
J Leukoc Biol. 2011 Aug;90(2):323-32. doi: 10.1189/jlb.0111046. Epub 2011 Apr 26.
8
Granulin is a soluble cofactor for toll-like receptor 9 signaling.颗粒蛋白前体是 Toll 样受体 9 信号转导的可溶性辅因子。
Immunity. 2011 Apr 22;34(4):505-13. doi: 10.1016/j.immuni.2011.01.018. Epub 2011 Apr 14.
9
Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.经CpG寡脱氧核苷酸激活的人初始B细胞将可溶性抗原呈递给CD8+ T细胞。
J Immunol. 2011 Feb 15;186(4):2080-6. doi: 10.4049/jimmunol.1001869. Epub 2011 Jan 14.
10
Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells.佐剂化佐剂:阳离子抗菌肽在树突状细胞中促进免疫调节寡核苷酸向 TLR9 的传递。
Vaccine. 2011 Jan 10;29(3):426-36. doi: 10.1016/j.vaccine.2010.11.003. Epub 2010 Nov 18.